Accuracy of helical computed tomography and [18F] fluorodeoxyglucose positron emission tomography for identifying lymph node mediastinal metastases in potentially resectable non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 23, Issue 33, 2005, Pages 8348-8356

  Pozo Rodríguez, Francisco ^a   Martín De Nicolás, José L ^a   Sánchez Nistal, María A ^a   Maldonado, Antonio ^a   García De Barajas, Santiago ^a   Calero García, Rosa ^a   Pozo, Miguel A ^a   Martín Escribano, Pedro ^a   Martín García, Isabel ^a   García Lujan, Ricardo ^a   Lopez Encuentra, Angel ^a   Arenas De Pablo, Angel ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINATED CONTRAST MEDIUM; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MEDIASTINOSCOPY; MEDIASTINUM METASTASIS; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SENSITIVITY AND SENSIBILITY; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; THORACOTOMY; COMPARATIVE STUDY; EVALUATION; FEMALE; LUNG TUMOR; MALE; MEDIASTINUM; OBSERVER VARIATION; PATHOLOGY; PREDICTION AND FORECASTING; PROSPECTIVE STUDY; RADIOGRAPHY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; SINGLE BLIND PROCEDURE;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MEDIASTINUM; OBSERVER VARIATION; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; SINGLE-BLIND METHOD; TOMOGRAPHY, SPIRAL COMPUTED;

EID: 33644684404     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.00.6361     Document Type: Article

References (31)

1. European Network of Cancer Registry. Lung cancer in Europe. Jerzy E. Tyczynsky, Freddie Bray, D Maxwell Parkin. 5/2004 update. http://www.encr.com
2. Naruke T, Tsuchiya R, Kondo H, et al: Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification: The Japanese experience. Ann Thorac Surg 71:1759-1764, 2001
3. Mortalidad por cáncer en España. Área de Epidemiologia Ambiental y Cáncer. Centro Nacional de Epidemiologí a. Instituto de Salud Carlos III, Ministry of Health, Spain. 5/2004 update. http://cne.isciii.es/cancer/mort2001.txt.
4. Downey RJ: Follow-up of patients with completely resected lung cancer. Chest 115:1487-1498, 1999
5. Dillemans B, Deneffe G, Verschakelen J, et al: Value of computed tomography and mediastinoscopy in preoperative evaluation of mediastinal nodes in non-small cell lung cancer. A study of 569 patients. Eur J Cardiothorac Surg 8:37-42, 1994
6. Toloza EM, Harpole L, Detterbeck F, et al: Invasive staging of non-small cell lung cancer: A review of the current evidence. Chest 123:S157-S166, 2003
7. Dales RE, Stark RM, Raman S: Computed tomography to stage lung cancer. Approaching a controversy using meta-analysis. Am Rev Respir Dis 141:1096-1101, 1990
8. Dwamena BA, Sonnad SS, Angobaldo JO, et al: Metastases from non-small cell lung cancer: Mediastinal staging in the 1990s-meta-analytic comparison of PET and CT. Radiology 213:530-536, 1999
9. Pautas, Carcinoma Broncogénico. Hospital Universitario 12 de Octubre, Madrid, Spain Lopez-Encuentra A, and Grupo Cooperativo del Carcinoma Broncogénico. 5/2004 update. http://www.mbeneumologia.org/mbe/pautas.aspx
10. Mountain CF, Dresler CM: Regional lymph node classification for lung cancer staging. Chest 111:1718-1723, 1997
11. Hamacher K, Coenen HH, Stocklin G: Efficient stereospecific synthesis of no-carrier-added 2-(18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 27:235-238, 1986
12. Arkin CF, Wachtel MS: How many patients are necessary to assess test performance? JAMA 263:275-278, 1990
13. Weder W, Schmid RA, Bruchhaus H, et al: Detection of extrathoracic metastases by positron emission tomography in lung cancer. Ann Thorac Surg 66:886-892, 1998
14. Pieterman RM, van Putten JW, Meuzelaar JJ, et al: Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 343:254-261, 2000
15. Hellwig D, Ukena D, Paulsen F, et al: [Meta-analysis of the efficacy of positron emission tomography with F-18-fluorodeoxyglucose in lung tumors. Basis for discussion of the German Consensus Conference on PET in Oncology 2000], Pneumologie 55:367-377, 2001
16. Toloza EM, Harpole L, McCrory DC: Non-invasive staging of non-small cell lung cancer: A systematic review of the current evidence. Chest 123:5137-3146, 2003
17. Positron emission tomography (PET) imaging in cancer management. Health Technology Assessment Report 2. Glasgow: Health Technology Board for Scotland. Bradbury I, Bonell E, Boynton J, et al: 2002. Update 6/2003. www.htbs .co.uk
18. Gould MK, Kuschner WG, Rydzak CE, et al: Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: A meta-analysis. Ann Intern Med 139:879-892, 2003
19. Gonzalez-Stawinski GV, lemaire A, Merchant F, et al: A comparative analysis of positron emission tomography and mediastinoscopy in staging non-small cell lung cancer. J Thorac Cardiovasc Surg 126:1900-1905, 2003
20. Cerfolio RJ, Ojha B, Bryant AS, et al: The role of FDG-PET scan in staging patients with nonsmall cell carcinoma. Ann Thorac Surg 76:861-866, 2003
21. Verhagen AF, Bootsma GP, Tjan-Heijnen VC, et al: FDG-PET in staging lung cancer; How does it change the algorithm? Lung Cancer 44:175-181, 2004
22. Kelly RF, Tran T, Holmstrom A, et al: Accuracy and cost-effectiveness of [18F]-2-fluorodeoxy-D-glucose-positron emission tomography scan in potentially resectable non-small cell lung cancer. Chest 125:1413-1423, 2004
23. Sheps SB, Schechter MT: The assessment of diagnostic tests. A survey of current medical research. JAMA 252:2418-2422, 1984
24. Reid MC, Lachs MS, Feinstein AR: Use of methodological standards in diagnostic test research. Getting better but still not good. JAMA 274:645-651, 1995
25. Bossuyt PM, Reitsma JB, Bruns DE, et al: Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD initiative. BMJ 326:41-44, 2003
26. Begg CB: Biases in the assessment of diagnostic tests. Stat Med 6:411-423, 1987
27. Lijmer JG, Bossuyt PM, Heisterkamp SH: Exploring sources of heterogeneity in systematic reviews of diagnostic tests. Stat Med 21:1525-1537, 2002
28. Van Tinteren H, Hoekstra OS, Smit EF, et al: Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: The PLUS multicentre randomised trial. Lancet 359:1388-1393, 2002
29. Reed CE, Harpole DH, Posther KE, et al: Results of the American College of Surgeons Oncology Group Z0050 trial: The utility of positron emission tomography in staging potentially operable non-small cell lung cancer. J Thorac Cardiovasc Surg 126:1943-1951, 2003
30. Viney RC, Boyer MJ, King MT, et al: Randomized controlled trial of the role of positron emission tomography in the management of stage I and II non-small-cell lung cancer. J Clin Oncol 22:2357-2362, 2004
31. Schirrmeister H, Hetzel M, Buck A: Staging of non-small-cell lung cancer with integrated PET and CT. N Engl J Med 349:1188-1190, 2003